Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00262093

Enrollment

200

Registered

2005-12-06

Start date

2005-11-30

Completion date

Unknown

Last updated

2007-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Eclampsia

Keywords

preeclampsia, sFlt1, PlGF, parity, angiogenesis

Brief summary

The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

Detailed description

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients. We intend to check the angiogenesis profile of primiparas as compared to multiparas.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

OTHER

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* Every delivery

Exclusion criteria

* Preeclampsia or pregnancy induced hypertension

Countries

Israel

Contacts

Primary ContactYuval Bdolah, MD, MSc

ybdolah@hadassah.org.il972-2-5844111

Backup ContactHadas Lemberg, PhD

lhadas@hadassah.org.il972-2-6777572

Outcome results